Bone turnover markers

Australian Family Physician

Volumn 42, Issue 5, 2013, Pages 285-287

  Coates, Penelope ^a  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

Biological markers; Bone remodelling; Osteoporosis

Indexed keywords

BIOLOGICAL MARKER; CALCIUM;

BONE; BONE DENSITY; BONE REMODELING; HUMAN; METABOLISM; NOTE; PHYSIOLOGY;

BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE REMODELING; CALCIUM; HUMANS;

EID: 84878349882     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (15)

1. Vasikaran S, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis Int 2011;22:391-420.
2. Seibel MJ. Biochemical markers of bone turnover part I: biochemistry and variability. Clin Biochem Rev 2005;26:97-122.
3. Garnero P, Hausherr E, Chapuy M-C, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996;11:1531-8.
4. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PJ. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000;15:1526-36.
5. Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004;34:599-604.
6. Cramer JA, Gold DT, Silverman SL, et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporosis Int 2007;18:1023-31.
7. Naylor K, Eastell R. Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol 2012;8:379-89.
8. Eastell R, Christiansen C, Grauer A, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 2011;26:530-7.
9. Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the Fracture Intervention Trial. J Bone Miner Res 2004;19:1250-8.
10. Recker RR, Marin F, Ish-Shalom S, et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 2009;24:1358-68.
11. McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013;126:13-20.
12. Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67:1167-73.
13. Koivula M-K, Risteli L, Risteli J. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum. Clin Biochem 2012;45:920-7.
14. Thomas SDC, Coates PS, Nordin BEC. Validation of a diagnostic cut-point of serum C-terminal telopeptide for postmenopausal osteoporosis. Clin Biochem Rev 2011;32:S23.
15. The Royal Australian College of General Practitioners. Clinical guideline for the prevention and treatment of osteoporosis in postmenopausal women and older men. February 2010. Available at www.racgp.org.au/download/documents/guidelines/musculoskeletal/racgp_osteo_guideline.pdf [Accessed 18 March 2013].